FDA clears UltraSight's AI platform for use with a broader range of existing ultrasound devices, aiding novice users in performing echocardiographic exams.
Key Details
- 1UltraSight's AI Echo Stewardship Platform now cleared by FDA for broader ultrasound compatibility.
- 2No new ultrasound equipment is required—compatible with handheld, laptop, and cart-based devices.
- 3Platform provides real-time, AI-assisted guidance for focused cardiac ultrasound (FoCUS) image acquisition.
- 4Aims to reduce variability and improve the usability of cardiac ultrasound by non-sonographer clinicians.
- 5Supports healthcare systems in scaling FoCUS exams without purchasing new hardware.
Why It Matters
By enabling AI-guided echocardiography on existing devices, this clearance lowers adoption barriers, expands cardiac imaging capabilities system-wide, and supports quality imaging by non-experts—potentially easing staff shortages and improving patient care accessibility.
Source
Cardiovascular Business
Related News
•AuntMinnie
In-House LLM Accurately Flags Critical Pediatric Radiology Findings
A locally deployed LLM system at Stanford Health achieved 99.7% sensitivity for detecting critical results in pediatric radiology reports, supporting workflow automation.
•Cardiovascular Business
FDA Clears Elucid's AI-Driven FFR-CT Solution for Cardiac Imaging
Elucid's FFR-IQ, an AI-powered noninvasive FFR-CT tool, receives FDA clearance for clinical use.
•Radiology Business
FDA Approves SimBioSys AI Tool for Breast Cancer Risk via MRI
SimBioSys received FDA clearance for TumorSight Risk, an AI tool assessing breast cancer recurrence risk using MRI.